NovoCure Limited (NASDAQ:NVCR) Receives $41.71 Consensus Target Price from Analysts
Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have been given an average rating of “Moderate Buy” by the eight brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to […]